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Abstract
Background: Epidemiological studies have observed a positive association between an earlier age at sexual
development and prostate cancer, but markers of sexual maturation in boys are imprecise and observational
estimates are likely to suffer from a degree of uncontrolled confounding. To obtain causal estimates, we examined
the role of pubertal development in prostate cancer using genetic polymorphisms associated with Tanner stage in
adolescent boys in a Mendelian randomization (MR) approach.
Methods: We derived a weighted genetic risk score for pubertal development, combining 13 SNPs associated with
male Tanner stage. A higher score indicated a later puberty onset. We examined the association of this score with
prostate cancer risk, stage and grade in the UK-based ProtecT case-control study (n = 2,927), and used the
PRACTICAL consortium (n = 43,737) as a replication sample.
Results: In ProtecT, the puberty genetic score was inversely associated with prostate cancer grade (odds ratio (OR)
of high- vs. low-grade cancer, per tertile of the score: 0.76; 95 % CI, 0.64–0.89). In an instrumental variable estimation of
the causal OR, later physical development in adolescence (equivalent to a difference of one Tanner stage between
pubertal boys of the same age) was associated with a 77 % (95 % CI, 43–91 %) reduced odds of high Gleason prostate
cancer. In PRACTICAL, the puberty genetic score was associated with prostate cancer stage (OR of advanced vs.
localized cancer, per tertile: 0.95; 95 % CI, 0.91–1.00) and prostate cancer-specific mortality (hazard ratio amongst cases,
per tertile: 0.94; 95 % CI, 0.90–0.98), but not with disease grade.
Conclusions: Older age at sexual maturation is causally linked to a reduced risk of later prostate cancer, especially
aggressive disease.
Keywords: Boys, Mendelian randomization, Prostate cancer, Puberty, Tanner scale
* Correspondence: richard.martin@bristol.ac.uk
1School of Social and Community Medicine, University of Bristol, Bristol, UK
2MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK
Full list of author information is available at the end of the article
© 2016 Bonilla et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Bonilla et al. BMC Medicine  (2016) 14:66 
DOI 10.1186/s12916-016-0602-x
Background
Prostate cancer is now the most frequently detected
cancer among men in Westernized countries [1]. Pros-
tatic intraepithelial neoplasia, a precursor of prostate
cancer, has been observed among men in their 20s,
suggesting that early-life exposures may play a role in
the development of prostate cancer [2] and provide
novel opportunities for prostate cancer prevention [3].
Circulating hormones, which rise during puberty, in
particular androgens and insulin-like growth factors
(IGFs), may play a role in prostate cancer initiation and
progression [4, 5], although the relevance of serum
androgen levels has recently been called into question
[6]. Age at onset of puberty may be a risk factor for
prostate adenocarcinoma in men given that exposure to
high levels of hormones takes place during the critical
window of prostate development in adolescence [3]. Age
of menarche is a well-known risk factor for breast cancer
[7], but it is yet unclear whether sexual maturation simi-
larly influences later life cancer events in men. However,
timing of puberty in boys is difficult to measure as it is
not defined by a specific event as in women (menarche);
thus, assessing it as a risk factor for prostate cancer in
men is challenging.
We investigated whether pubertal development influ-
ences risk of prostate cancer in a population-based cohort.
We used a genetic score comprised of single nucleotide
polymorphisms (SNPs) associated with Tanner genital
stage in adolescent boys [8, 9], as a surrogate for the onset
and progression of pubertal changes, and we determined
associations of this genetic score with prostate cancer risk,
stage and grade. The Tanner scale is a widely used 5-point
scale that rates breast development in girls, genital devel-
opment in boys, and pubic hair growth in both [10]. Using
a genetic score instead of directly assessed Tanner stage,
in an approach known as Mendelian randomization
(MR) [11], allows stronger causal inferences because
genetic variants are usually unaffected by non-genetic
confounding, reverse causality, or measurement error,
which underlie the problematic interpretation of ob-
servational studies [11, 12].
Methods
Subjects
This is a case-control study nested within a multicenter
randomized controlled trial of treatments for prostate-
specific antigen (PSA)-detected prostate cancer: the
Prostate Testing for cancer and Treatment (ProtecT)
study (ISRCTN20141297) [13]. During recruitment to
the ProtecT study between 2001 and 2009, over 100,000
men aged 50–69 years at 337 general practices in nine
UK centres (Birmingham, Bristol, Cambridge, Cardiff,
Edinburgh, Leeds, Leicester, Newcastle, Sheffield) were
offered a PSA test at a community-based ‘prostate check
clinic’, and those with raised levels (≥3 ng/mL) were
offered a diagnostic biopsy [14]. Detected tumours were
all histologically confirmed and clinically staged using
the TNM system [15]. In the current analysis, cancer
stages T1-T2 were categorized as ‘localized’; and T3-T4
as ‘locally advanced’, because few tumors had meta-
stasized. Histologic material obtained at biopsy was
assigned a Gleason score by specialist uropathologists
following a standard proforma and, for the purposes of
this study, categorized as low- (score ≤6) or high-grade
(score ≥7) cancers. All men without evidence of prostate
cancer were eligible for selection as controls; that is,
men with a PSA <3 ng/mL or a raised PSA (≥3 ng/mL)
combined with at least one negative biopsy and no sub-
sequent prostate cancer diagnosis during the follow-up
protocol. We selected one stratum-matched control for
each case from those men who had provided a non-
fasting blood sample at the prostate check clinic.
Controls were randomly selected from the same stratum,
i.e. 5-year age-band (age at PSA test) and GP/family
practice, as cases.
The working dataset consisted of 2,927 individuals
(1,136 cases, 1,791 controls) of European descent with
available genotype and phenotype information. All men
provided written informed consent prior to inclusion in
the study. Trent Multicentre Research Ethics Committee
(MREC) approved the ProtecT study (MREC/01/4/025)
and the associated ProMPT study which collected bio-
logical material (MREC/01/4/061; see Additional file 1:
Supplementary Methods for further details).
Genetic risk score
We derived a genetic risk score for pubertal develop-
ment in boys based on associations between 13 SNPs
and Tanner genital stage in males between 12.6 and
15 years of age described in two recent genome-wide
association studies (GWAS) of sexual maturation [8, 9].
All SNPs in the score were associated with Tanner stage
in boys (independently of whether they were also associ-
ated with Tanner stage in girls or in a combined sample
of boys and girls), and they had previously been associ-
ated with age at menarche [8, 16], although not always
in the direction consistent with their association with
Tanner genital stage [9]. Variants in the same gene were
included in the score provided their linkage disequilib-
rium, r2, was lower than 0.8.
Scores are used instead of individual genetic variants
because they are likely to explain a larger proportion of
trait variability and therefore represent stronger proxies
for the exposure [12]. Scores were calculated by summing
up the dosages of the risk alleles at all 13 SNPs in each
individual, weighted by the effect size of the variant in
males as reported in the discovery GWAS [8, 9], in such a
way that a unit increase in the score corresponded
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approximately to one risk allele. Risk alleles were those
associated with a lower Tanner stage (i.e. delayed pubertal
development). Polymorphisms included in the score are
shown in Table 1.
Statistical analysis
Associations of individual SNPs and the multiple SNP
score for pubertal development with case/control status
and other binary outcomes (localized [reference] vs.
locally advanced stage and low [reference] vs. high
grade) were determined using logistic regression, with
adjustment for age, study center, and the 10 principal
components which defined the population structure.
The genetic score was entered into the regression
models as a categorical variable with three levels (tertiles).
We also used this variable to test for linearity of effect and
compare prostate cancer risk among men in the lowest
and highest tertiles (i.e. with the earliest and latest sexual
maturation, respectively). All analyses were carried out in
Stata 13 (StataCorp LP, College Station, TX).
We plotted the effect of each SNP in the genetic score
on Tanner stage in approximately 13- to 15-year-old
boys against the corresponding effect on high-grade
prostate cancer, the disease outcome with the strongest
association with the score. The likelihood of bias due to
overall directional pleiotropy was formally evaluated
with MR-Egger regression [17]. MR-Egger regression
also provides an unbiased effect estimate (see definitions
in Additional file 1: Supplementary Methods).
We did not have data on Tanner stage measured in
adolescence in ProtecT men, and therefore could not
estimate its association with the genetic score in
ProtecT, in order to run a typical instrumental variable
analysis. However, we used a recently developed MR
method (summarized data allele score with correlated
variants) that provides an estimate of the causal effect of
the exposure (i.e. Tanner stage) on the outcome of
interest (i.e. prostate cancer) using information on the
association of individual SNPs in the score with expos-
ure and outcome [18]. We obtained the effect estimates
Table 1 SNPs included in the pubertal development genetic risk score in the ProtecT study
SNP Nearest gene
(distance)
Chr Positiona Tanner stage
decreasing/
other allele
Tanner stage decreasing
allele frequency
(ProtecT controls)b
Tanner stage
decreasing allele
frequency (CEU)
Hardy–Weinberg
equilibrium
P value
Gene function
rs2274465 KDM4A 1 44121557 C/G 0.664 0.676 0.9 Histone
demethylation
rs6427782 NR5A2 (+198 kb) 1 199798339 A/G 0.510 0.556 0.005 DNA binding/
steroid hormone
receptor activity
rs6762477 RBM6 3 50093209 A/G 0.547 0.551 0.6 Regulation of
alternative splicing
rs2153127 LIN28B (+36 kb) 6 105348544 T/C 0.530 0.515 0.8 Cell reprogramming
rs7759938 LIN28B (+6 kb) 6 105378954 C/T 0.318 0.373 1.0 Cell reprogramming
rs7821178 PEX2 (–181 kb) 8 78093837 C/A 0.665 0.658 0.1 Peroxisome
biogenesis
rs10453225 TMEM38B (–381 kb) 9 108920220 G/T 0.681 0.700 0.2 Maintenance of
intracellular
calcium release
rs2090409 TMEM38B (–428 kb) 9 108967088 C/A 0.680 0.688 0.3 Maintenance of
intracellular calcium
release
rs10739221 TMEM38B (–522 kb) 9 109060830 C/T 0.772 0.770 0.5 Maintenance of
intracellular
calcium release
rs1324913 KLF12 13 74635588 T/G 0.338 0.312 0.6 Transcription factor/
gene expression
regulation
rs12915845 DET1 15 89042467 C/T 0.587 0.582 0.1 Development
regulation
rs246185 MKL2 (–35 kb) 16 14395432 C/T 0.313 0.300 0.6 Regulation of
immediate early
genes/muscle genes
rs12446632 GPRC5B (–38 kb) 16 19935389 A/G 0.146 0.127 0.8 Modulation of
insulin secretion
aPosition based on GRCh37.p13 assembly
bn = 1,791
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of SNPs on Tanner stage at approximately 13–15 years
from published GWAS data [8, 9].
Replication analyses were carried out in the PRAC-
TICAL consortium (PRostate cancer AssoCiation group
To Investigate Cancer-Associated aLterations in the
genome) to test the association of the puberty genetic
score with prostate cancer risk and progression. Overall,
there were 45,928 individuals of European ancestry, of
which 22,160 prostate cancer cases and 21,577 controls
had genotype data available after applying quality control
procedures. Additionally, amongst men with prostate
cancer in PRACTICAL, we estimated associations of the
puberty score with 15-year all-cause and prostate
cancer-specific mortality (as an indication of long-term
survival) using Cox proportional hazards regression with
date at diagnosis as the start date and date at death or
final follow-up as the exit date, adjusted for age at diag-
nosis and 15 principal components, with robust standard
errors to account for within study clustering. All studies
in the consortium have the relevant Institutional
Review Board approval in each country in accordance
with the Declaration of Helsinki. More detailed infor-
mation is provided in the consortium website (http://
practical.ccge.medschl.cam.ac.uk) and Additional file 1:
Supplementary Methods and Tables S1 and S2.
Results
ProtecT
Men with prostate cancer were on average older, had
less benign prostatic hyperplasia (BPH), a lower body
mass index (BMI), more relatives with prostate cancer,
lower IGF-I, and higher IGF-II and IGF binding protein
(BP)-3 levels than controls (Table 2). The IGF-I:IGFBP-3
molar ratio, an indicator of bioavailable IGF-I, was con-
sequently lower in patients; 30 % of men with prostate
cancer were classified as having high-grade disease
(Gleason score ≥7), and 12 % as having locally advanced
disease (TNM stages T3-T4).
The genetic score was normally distributed (Additional
file 1: Figure S1) and for the most part not correlated
with population stratification axes (data not shown).
We found evidence of an inverse association between
our genetic score for pubertal development in boys and
prostate cancer, i.e. the higher the score and, thus, the
later the sexual maturation, the lower the risk for
prostate cancer. The association was particularly strong
for Gleason grade (odds ratio (OR) low- vs. high-grade
disease, per tertile: 0.76; 95 % CI, 0.64–0.89; P = 0.001;
Table 3). A dose-response effect of the genetic score in
tertiles on high-grade prostate cancer was observed.
Men in the highest score tertile (representing the most
sexually immature individuals at a specific age) had a
43 % (95 % CI, 21–59 %) lower risk of high- versus low-
grade disease than men in the lowest tertile (Table 4).
The reported effect of each SNP in the score on Tanner
stage in boys [8, 9] was correlated with the corresponding
effect on having high-, compared to low-grade, prostate
cancer (R2 ~ 31 %; Additional file 1: Table S3, Fig. 1).
Overall, there was no evidence of an association be-
tween the genetic score and potential confounders among
controls, such as age, BMI, weight, birthweight, BPH, fam-
ily history of prostate cancer, or diabetes. No association
between the genetic score and PSA was found either.
Marginal positive associations with leg length, a trait
affected by the timing of puberty [19], and adult height
were detected. In addition, we uncovered weak associ-
ations with IGFBP-2 and IGFBP-3 serum levels, as
well as with the IGF-I:IGBP-3 molar ratio (Additional
file 1: Table S4).
Using an estimated genetic score with summarized
data [18] we determined that there would be a substan-
tial reduction in high-grade (compared to low-grade)
prostate cancer per unit decrease in Tanner stage in re-
lation to peers (OR: 0.23; 95 % CI, 0.09–0.57; P = 0.002).
The MR-Egger’s test did not suggest the presence of dir-
ectional pleiotropy (P for intercept >0.05; see symmet-
rical funnel plot in Additional file 1: Figure S2), and gave
a similar causal estimate to that obtained with the allele
score with the summarized data method (OR: 0.16; 95 %
CI, 0.04–2.94; P = 0.2). No heterogeneity was apparent in
the causal estimates obtained from each genetic variant
individually (I2 = 0.0 %, P = 1.0).
PRACTICAL
We created a weighted genetic score with 12 of the 13
SNPs used in ProtecT, as rs1324913 was not available in
PRACTICAL. Information on SNPs in the score is
provided in Additional file 1: Table S5, and the score dis-
tribution is shown in Additional file 1: Figure S1. No
correlation between the Tanner score and principal
components was evident, and similarly, the score was
not associated with age at diagnosis, family history, or
method of disease detection (not shown).
In a meta-analysis of 21 studies included in PRAC-
TICAL, the genetic score was associated with prostate
cancer risk, such that a higher score – and therefore, a
delayed maturation – showed a protective effect (OR per
tertile: 0.97; 95 % CI, 0.94–1.00; P = 0.03). A slightly
bigger effect was found with prostate cancer stage (local-
ized vs. advanced, OR per tertile: 0.95; 95 % CI, 0.91–
1.00; P = 0.03; Fig. 2) but not with grade (low vs. high
grade, OR per tertile: 0.98; 95 % CI, 0.95–1.02; P = 0.4;
Additional file 1: Table S6). Heterogeneity between studies
was low (I2 < 33 %; P >0.05).
There were 15 studies with mortality data in PRAC-
TICAL. Overall, the average time to death or final
follow-up was 7 years, with a maximum ranging from
approximately 6 (in PCMUS) to 38 years (in Tampere).
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The genetic score was associated with 15-year prostate
cancer-specific mortality amongst men with prostate
cancer (hazard ratio (HR) per tertile: 0.94; 95 % CI,
0.90–0.98; P = 0.01), and marginally with 15-year all-
cause mortality (HR per tertile: 0.97; 95 % CI, 0.95–1.00;
P = 0.04). The proportional hazards assumption was not
met (P <0.001), probably due to the fact that up to
5 years post-diagnosis there do not appear to be differ-
ences in survival between individuals with different
numbers of risk alleles (i.e. alleles associated with later
pubertal timing; Additional file 1: Figure S3).
We estimated the effect of being ranked a unit lower
in the Tanner stage (for the same age) on 15-year
prostate cancer-specific mortality as HR 0.62 (95 % CI,
0.49–0.78; P <0.001). The corresponding funnel plot and
MR-Egger results, which did not uncover evidence of
pleiotropy, are shown in Additional file 1: Figure S4.
Table 2 Clinical characteristics of prostate cancer cases and controls in the ProtecT study
Cases Controls n P value
Total, n 1,136 1,791 2,927
Age, years 62.2 ± 5.1 61.6 ± 5.2 2,927 0.003
PSA, ng/mL 8.5 ± 15.4 1.1 ± 1.3 2,925 <0.001
Gleason grade, % (<7/≥7) 70.0/30.0 n/a 1,135
TNM stage, % (localized/advanced) 88.4/11.6 n/a 1,136
BPH, % (no/yes)a 92.7/7.3 89.0/11.0 1,363 0.02
BMI, kg/m2 27.0 ± 3.7 27.5 ± 4.1 1,973 0.01
Height, cm 176.4 ± 7.0 175.9 ± 6.9 2,078 0.2
Weight, kg 84.5 ± 13.0 85.9 ± 14.6 2,677 0.02
leg length, cm 76.7 ± 4.8 76.5 ± 4.6 2,055 0.3
Birthweight, g 3,437.2 ± 744.9 3,476.1 ± 663.4 939 0.4
Family history, % (no/yes)b 92.7/7.3 95.0/5.0 2,908 0.01
Diabetes, % (no/yes)c 92.8/7.2 91.1/8.9 1,895 0.2
IGF-I, ng/mL 156.1 ± 55.8 163.2 ± 57.0 1,756 0.01
IGF-II, ng/mL 862.1 ± 323.6 733.7 ± 265.3 1,720 <0.001
IGFBP-2, ng/mL 731.5 ± 426.0 726.2 ± 444.7 1,745 0.5d
IGFBP-3, ng/mL 4,673.6 ± 1,041.9 4,370.8 ± 1,055.7 1,711 <0.001
IGF-I:IGFBP-3 molar ratioe 0.12 ± 0.04 0.14 ± 0.06 1,711 <0.001d
Continuous variables: mean ± SD
Two-sided t-tests and χ2 tests were used to analyze continuous and categorical variables, respectively
PSA Prostate-specific antigen, BMI Body mass index, BPH Benign prostatic hyperplasia, IGF Insulin-like growth factor, IGFBP Insulin-like growth factor
binding protein
an cases = 682, n controls = 681
bn cases = 1,131, n controls = 1,777
cn cases = 735, n controls = 1,160
dP value obtained from analysis of natural log transformed variable
eIGF-I:IGFBP-3 molar ratio = 0.13*[IGF-I]:0.036*[IGFBP-3]
Table 3 Pubertal development genetic risk score and prostate
cancer risk, stage and grade in the ProtecT study
Trait n OR 95 % CI P value
Control/case (0/1) 2,927 0.95 0.87–1.04 0.3
Gleason score (0:≤6/1:≥7)a 1,135 0.76 0.64–0.89 0.001
Stage (0:localised/1:locally advanced) 1,136 0.80 0.64–1.01 0.06
BPH (0:no/1:yes) 1,363 1.11 0.88–1.40 0.4
ORs indicate effects per tertile increase in the genetic score, adjusted by age,
recruitment centre and 10 principal components for population structure
a0 corresponds to the reference category
BPH Benign prostatic hyperplasia, CI Confidence intervals, OR Odds ratio
Table 4 Odds ratios (ORs) for high- vs low-grade prostate cancer
by pubertal development genetic risk score tertiles in the
ProtecT study
Genetic score tertiles OR 95 % CI P value
T1 Reference 0.003
T2 0.79 0.58–1.07
T3 0.57 0.41–0.79
High-grade prostate cancer = Gleason ≥7
Low-grade prostate cancer = Gleason ≤6
OR adjusted by age, recruitment centre and 10 principal components for
population structure
n = 1,135
CI Confidence intervals
Bonilla et al. BMC Medicine  (2016) 14:66 Page 5 of 11
Discussion
Main findings
In a study of PSA-detected prostate cancer cases and
controls we found strong evidence that a genetic score,
comprised of SNPs associated with Tanner stage in
approximately 13- to 15-year-old boys, was inversely
associated with prostate cancer progression. A later
pubertal development (expected among those with
higher genetic score values) lowered the risk of develop-
ing high-grade disease, a possible clinically relevant sub-
type because of its stronger relationship than low-grade
disease to progression.
Replication analysis using 21 prostate cancer studies
across Europe, the USA and Australia in the PRAC-
TICAL consortium, uncovered a weak inverse associ-
ation between prostate cancer risk and stage and the
puberty genetic score, with a reduced effect detected on
disease grade. However, we found a stronger association
of the score with prostate cancer-specific mortality up to
15 years after diagnosis, indicating that (on average)
men whose sexual maturation was later than their peers
were less likely to die due to the disease than those
whose onset of puberty was earlier. This is in agreement
with our findings in ProtecT, regarding the association
of earlier puberty with high-grade disease, as men with
more aggressive cancer tend to have a poorer prognosis
[20]. It is possible that differing definitions of low- and
high-grade prostate cancer across studies may have pre-
vented the detection of an effect of the puberty score on
this phenotype, with mortality being a stronger and
more clear-cut marker of an aggressive disease. There
were also differences between studies in method of
disease detection: the cases enrolled in ProtecT were
PSA-detected, whereas the majority of men in the
PRACTICAL studies were clinically identified. Addition-
ally, in PRACTICAL, there was a wide variation in the
proportion of men with a positive family history of pros-
tate cancer, which ranged from as low as 2.4 % in EPIC
to 42.4 % in WUGS (conversely, the proportion of men
with a positive family history in ProtecT was ~6 %).
Mechanisms explaining the observed associations
It has been suggested that endogenous androgen and
IGF-I hormones may underlie the relationship between
puberty timing and prostate cancer risk [4, 5]. The
concentrations of these hormones increases markedly
during puberty and are likely to be especially influential
on the prostate gland as it becomes fully developed at
Fig. 1 Effect of Tanner stage change in boys on the risk of developing
high-grade prostate cancer. In ProtecT, proportional risk reduction for
high-grade prostate cancer (Gleason ≥7) for each SNP plotted against
each SNP’s absolute effect on lowering Tanner stage. The trend line,
set to intercept the axes at the origin, represents the percentage risk
reduction for high-grade disease per unit decrease in Tanner stage.
Excluding SNP rs6427782, which was out of Hardy–Weinberg equilibrium
pre-Bonferroni correction for multiple testing, from the plot did not
produce an appreciable change in the results. Tanner genital stage in
boys was treated as a quantitative trait on a scale of 1–5, according to
the studies where the associated SNPs were first described [8, 9]
Fig. 2 Pubertal development genetic risk score and prostate cancer
risk (top) and stage (bottom) in the PRACTICAL consortium
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this time [21]. Because the prostate is still maturing,
puberty may be an important biological window at
which early life exposures could have long-term effects
on the prostate [3].
Androgens play a central role in the etiology of prostate
cancer, as prostate cancer is dependent on androgen re-
ceptor activation for growth and survival [22]. A delayed
pubertal onset may reduce the length of time an individual
is exposed to high androgen levels during a period when
the prostate is particularly susceptible to carcinogenic
exposures [3].
IGF-I is a potent mitogen and inhibitor of apoptosis
that mediates growth during childhood and adolescence
and, consequently, stimulates carcinogenesis. IGF-I
levels increase from birth to a pubertal peak before
declining steadily from young adulthood [23, 24]. It is
possible that a younger age at the initiation of puberty is
linked to an increase in prostate cancer risk by its
association with higher IGF-I levels. Serum IGF-I has
been positively associated with an earlier pubertal age in
an observational study examining adult IGF-I levels,
suggesting that higher pre-pubertal IGF-I (if reflected by
higher adult IGF-I) may accelerate childhood growth
and the start of puberty [24].
In our study, the puberty genetic score was not associ-
ated with circulating IGF-I, although the effect appeared
to be in the direction anticipated [24], but we observed
an inverse association with the IGF-I:IGFBP-3 molar
ratio, suggesting that an earlier pubertal development
may be influenced by higher levels of bioavailable IGF-I.
The weakly positive association of the genetic score
with adult leg length and height agrees with studies that
showed that earlier age at puberty was associated with
shorter stature, primarily attributable to shorter leg
length, in US women [25] and Swedish men [19].
Growth in leg length, an indicator of pre-pubertal living
conditions, on the other hand, has been positively
associated with IGF-I levels in UK children, particularly
boys [26].
Our finding that a younger age at sexual maturation
increases the risk of developing high-grade prostate
cancer, and of dying due to the disease, strengthens the
idea of the existence of trade-offs between reproductive
success and health. MR analysis suggests that there may
be a causal relationship between early life environments
that promote an accelerated onset of puberty under
conditions of uncertainty (e.g. in cases of familial stress
due to low income, marital conflict or father absence),
so as to favour reproduction, and a detrimental effect on
health and longevity in the long term [27, 28].
Strengths and limitations
Studies of puberty in men are problematic because its
initiation is not defined as a single event in the way that
menarche is. In addition, in studies of middle aged and
elderly men, an attempt to measure puberty is likely to
suffer from recall bias. The genetic score represents a
more accurate instrument to assess the causality of the
association of pubertal development and prostate cancer
risk. The association with leg length provides to some
extent a validation of the genetic score in the ProtecT
population.
A genetic score is unlikely to be associated with
non-genetic confounders, which frequently obscure
the interpretation of observational data, and this is, in
fact, the case in our study with respect to a few
measured confounders.
As the genetic score in our study was not associated
with age, PSA, BMI, diabetes, or BPH, we believe that its
association with prostate cancer does not represent an
artefact of detection due to, for instance, men who are
seen more frequently by a doctor having an incidental
diagnosis of prostate cancer.
One important assumption in MR is that the instrument
(i.e. the genetic score) should be associated with the
outcome of interest (i.e. prostate cancer) only via the
exposure (i.e. pubertal development). Some SNPs in the
score have been associated with height (P <0.05, http://
www.gwascentral.org/index) while four of them are
located near genes (LIN28B and TMEM38B) recently
associated with sitting height ratio and found to dispro-
portionately affect leg length [29]. However, this could be
an example of mediated pleiotropy (where a single process
influences a cascade of events) [30] and as such it does
not undermine our findings. Furthermore, a formal test of
the assumption of no pleiotropy, implemented using MR-
Egger’s regression, found no evidence of a violation of this
principle.
Replication of our findings as well as uncovering the
potential mechanisms through which the timing of
puberty might affect the progression of prostate cancer
were likely hindered by differences in phenotype ascer-
tainment in PRACTICAL studies.
Comparison with existing literature
Few studies have examined the role that pubertal devel-
opment has on the initiation and progression of prostate
cancer, in contrast to the more extensive research on age
at menarche and breast cancer. This research shows that
an earlier age at menarche is reliably associated with
greater breast cancer risk [31]. Given the difficulties in
defining puberty among males, studies have used a
variety of traits as proxies, mainly age at different life
events such as shaving initiation [21, 32], first sexual
intercourse [33–36], first ejaculation [37], peak height
velocity [24], attainment of adult height [38], as well as
the well-established Tanner scale [10]. Results from
studies that assessed these variables with respect to
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prostate cancer showed that later growth relative to
peers [37], height attainment [38], age at first sexual
intercourse [33–36], and being older than 16 at first
ejaculation [37] were all associated in a protective
direction with prostate cancer. Older age at initiation of
shaving was also protective but only among African
Americans [21]. As far as we know, no observational
study to date has used Tanner stage to investigate the
relationship between pubertal development and prostate
cancer, so a comparison with our MR findings is not
possible.
Conclusions
Using an MR approach, we have found evidence that
experiencing a later sexual maturation reduces prostate
cancer risk, especially that of aggressive prostate cancer,
as well as mortality owing to the disease. The mecha-
nisms that underlie this relationship may involve the
androgenic or IGF pathways, but additional MR studies,
using specific instruments for these exposures, should be
carried out to investigate this further. Although altering
pubertal timing is not a viable prostate cancer prevention
strategy there is public health value in identifying those in-
dividuals who are more likely to have a worse prognosis
[3]. On the other hand, if pubertal development is shown
to be driven by increased IGF-I levels, then dietary
interventions to regulate its course could potentially be
considered.
Availability of data and materials
Summary data is provided in Additional file 2.
Additional files
Additional file 1: Tables S1 – S6. Figures S1–S4. Supplementary
Methods. Definitions. Supplementary References. (DOCX 214 kb)
Additional file 2: Summary data of the association of each SNP in the
pubertal development genetic risk score with exposure and outcomes in
the PRACTICAL consortium. (XLSX 13 kb)
Abbreviations
BMI: Body mass index; BPH: Benign prostatic hyperplasia; GWAS: Genome-wide
association study; IGF: Insulin-like growth factor; IGFBP: Insulin-like growth factor
binding protein; LD: Linkage disequilibrium; MR: Mendelian randomization;
PSA: Prostate-specific antigen; SNP: Single nucleotide polymorphism.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RMM, SJL and GDS developed the hypothesis and secured funding. CB
carried out statistical analyses. CB, SJL and RMM wrote the first draft of the
paper. ML organized the genome-wide genotyping of participants in the
ProtecT study. JLD, FCH and DEN are PIs of the ProtecT (Prostate Testing for
Cancer and Treatment) study. The remaining authors are PIs of the studies
contributing to the PRACTICAL consortium. All PIs contributed to the conception,
design, and management of each study and of the consortium as a whole. All
authors critically commented on and approved the final submitted
version of the paper.
Authors’ information
JLD, FCH and DEN are NIHR Senior Investigators.
Acknowledgments
The authors thank the tremendous contribution of all members of the
ProtecT study research group, and especially the following, who were
involved in this research (Prasad Bollina, Sue Bonnington, Lynn
Bradshaw, James Catto, Debbie Cooper, Michael Davis, Liz Down,
Andrew Doble, Alan Doherty, Garrett Durkan, Emma Elliott, David Gillatt,
Pippa Herbert, Peter Holding, Joanne Howson, Mandy Jones, Roger
Kockelbergh, Howard Kynaston, Teresa Lennon, Norma Lyons, Hing
Leung, Malcolm Mason, Hilary Moody, Philip Powell, Alan Paul, Stephen
Prescott, Derek Rosario, Patricia O’Sullivan, Pauline Thompson, Sarah
Tidball). We thank Gemma Marsden and Luke Marsden, who processed
the blood samples at the biorepository, and Rajeev Kumar, data
manager. We also would like to thank the Center National de
Génotypage, Evry, France, for genotyping the ProtecT samples. We also
thank Stephen Burgess for his help with some of the Mendelian
randomization analyses, and Theresa Redaniel for assistance with the
survival analysis.
The authors are grateful for the provision of the additional epidemiological
data by the NHS R&D Directorate supported Prodigal study and the ProMPT
(Prostate Mechanisms of Progression and Treatment) collaboration which is
supported by the National Cancer Research Institute (NCRI) formed by the
Department of Health, the Medical Research Council and Cancer Research
UK (G0500966/75466).
The Collaborative Oncological Gene-environment Study (COGS), within
which the PRACTICAL consortium was assembled, would not have been
possible without the contributions of the following: Per Hall (COGS), Douglas
F. Easton, Paul Pharoah, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang
(BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Douglas F. Easton,
Ali Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia
Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch, Ken Offit
(CIMBA), Joe Dennis, Alison M. Dunning, Andrew Lee, Ed Dicks, Craig Luccarini,
and the staff of the Centre for Genetic Epidemiology Laboratory; Javier Benitez,
Anna Gonzalez-Neira, and the staff of the CNIO genotyping unit; Jacques Simard,
Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière,
Frederic Robidoux, and the staff of the McGill University and Génome
Québec Innovation Centre; Stig E. Bojesen, Sune F. Nielsen, Maren
Weischer, Børge G. Nordestgaard, and the staff of the Copenhagen DNA
laboratory; and Julie M. Cunningham, Sharon A. Windebank, Christopher
A. Hilker, Jeffrey Meyer, and the staff of the Mayo Clinic Genotyping
Core Facility.
The funding sources had no role in the design and conduct of the study,
collection, management, analysis and interpretation or preparation, review,
or approval of the article.
Funding
This work was supported by the World Cancer Research Fund (2011/419)
and Cancer Research UK (C18281/A19169). The Integrative Epidemiology
Unit (IEU) is supported by the MRC and the University of Bristol
(G0600705, MC_UU_12013/19), and the Integrative Cancer Epidemiology
Programme is supported by Cancer Research UK programme grant
C18281/A19169. The National Institute for Health Research (NIHR) Bristol
Nutrition Biomedical Research Unit is funded by the NIHR and is a
partnership between University Hospitals Bristol NHS Foundation Trust
and the University of Bristol. The ProtecT study is supported by the UK
NIHR Health Technology Assessment (HTA) Programme (HTA 96/20/99;
ISRCTN20141297). Funding for PRACTICAL and the iCOGS infrastructure
came from: the European Community’s Seventh Framework Programme
under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS),
Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174,
C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/
A16565), the National Institutes of Health (CA128978), and Post-Cancer GWAS
initiative (1U19 CA148537, 1U19 CA148065 and 1U19 CA148112 – the
GAME-ON initiative), the Department of Defence (W81XWH-10-1-0341), the
Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks
of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research
Foundation, and the Ovarian Cancer Research Fund. We acknowledge support
from the NIHR to the Biomedical Research Centre at The Institute of Cancer
Research and The Royal Marsden NHS Foundation Trust.
Bonilla et al. BMC Medicine  (2016) 14:66 Page 8 of 11
The PRACTICAL CONSORTIUM (in addition to those named in the
author list)
Additional members from the consortium are: Margaret Cook1, Angela
Morga2, Artitaya Lophatananon3,4, Cyril Fisher2, Daniel Leongamornlert2,
Edward J. Saunders2, Emma J. Sawyer2, Koveela Govindasami2, Malgorzata
Tymrakiewicz2, Michelle Guy2, Naomi Livni2, Rosemary Wilkinson2, Sara
Jugurnauth-Little2, Steve Hazel2, Tokhir Dadaev2, Melissa C. Southey5, Liesel
M. Fitzgerald6, John Pedersen7, John Hopper8, Ami Karlsson9, Carin
Cavalli-Bjoerkman9, Jan-Erik Johansson9, Jan Adolfson9, Markus Aly9,10,
Michael Broms9, Paer Stattin9, Brian E. Henderson11, Fredrick Schumacher11,
Anssi Auvinen12, Kimmo Taari13, Liisa Maeaettaenen14, Paula Kujala15, Teemu
Murtola16,17, Teuvo LJ Tammela17, Csilla Sipeky18, Martin Andreas Roder19,
Peter Iversen19, Peter Klarskov20, Sune F. Nielsen21,22, Maren Weischer21,22,
Tim J. Key23, Hans Wallinder24, Sven Gustafsson24, Angela Cox25, Anne
George26, Athene Lane27, Gemma Marsden28, Michael Davis27, Paul Brown27,
Paul Pharoah29, Lisa B. Signorello30,31, Wei Zheng32, Shannon K. McDonnell33,
Daniel J. Schaid33, Liang Wang33, Lori Tillmans33, Shaun Riska33, Thomas
Schnoeller34, Kathleen Herkommer35, Manuel Luedeke34, Walther Vogel36,
Dominika Wokozorczyk37, Jan Lubiski37, Wojciech Kluzniak37, Katja Butterbach38,
Christa Stegmaier39, Bernd Holleczek39, Babu Zachariah40, Hui-Yi Lim41, Hyun
Park40, James Haley40, Julio Pow-Sang40, Maria Rincon40, Selina Radlein40,
Thomas Sellers40, Chavdar Slavov42, Aleksandrina Vlahova43, Atanaska Mitkova44,
Darina Kachakova44, Elenko Popov42, Svetlana Christova43, Tihomir Dikov43,
Vanio Mitev44, Allison Eckert45, Angus Collins45, Glenn Wood45, Greg Malone45,
Judith A. Clements45,46, Kris Kerr45, Megan Turner45, Pamela Saunders45, Peter
Heathcote45, Gail Risbridger45, Wayne Tilley45, Lisa Horvath45, Trina Yeadon45,
Srilakshmi Srinivasan46, Leire Moya46, Amanda Spurdle47, Joana Santos48,
Carmen Jerónimo48, Paula Paulo48, Pedro Pinto48, Rui Henrique48, Sofia Maia48,
Agnieszka Michael49, Andrzej Kierzek49, and Huihai Wu49.
1Centre for Cancer Genetic Epidemiology, Department of Public Health and
Primary Care, University of Cambridge, Strangeways Laboratory, Worts
Causeway, Cambridge CB1 8RN, UK; 2The Institute of Cancer Research,
Sutton, UK; 3Institute of Population Health, University of Manchester,
Manchester, UK; 4Warwick Medical School, University of Warwick, Coventry,
UK; 5Genetic Epidemiology Laboratory, Department of Pathology, The
University of Melbourne, Grattan Street, Parkville, Victoria 3010, Australia;
6Cancer Epidemiology Centre, The Cancer Council Victoria, 615 St Kilda Road,
Melbourne, Victoria, Australia; 7Tissupath Pty Ltd., Melbourne, Victoria 3122,
Australia; 8Centre for Epidemiology and Biostatistics, Melbourne School of
Population and Global Health, The University of Melbourne, Victoria,
Australia; 9Department of Medical Epidemiology and Biostatistics, Karolinska
Institute, Stockholm, Sweden; 10Department of Clinical Sciences at Danderyds
Hospital, Stockholm, Sweden; 11Department of Preventive Medicine, Keck
School of Medicine, University of Southern California/Norris Comprehensive
Cancer Center, Los Angeles, California, USA, 12Department of Epidemiology,
School of Health Sciences, University of Tampere, Tampere, Finland;
13Department of Urology, Helsinki University Central Hospital and University
of Helsinki, Helsinki, Finland; 14Finnish Cancer Registry, Helsinki, Finland;
15Fimlab Laboratories, Tampere University Hospital, Tampere, Finland;
16School of Medicine, University of Tampere, Tampere, Finland; 17Department
of Urology, Tampere University Hospital and Medical School, University of
Tampere, Finland; 18Medical Biochemistry and Genetics, Institute of
Biomedicine, University of Turku, Finland; 19Copenhagen Prostate Cancer
Center, Department of Urology, Rigshospitalet, Copenhagen University
Hospital, Tagensvej 20, 7521, DK-2200 Copenhagen, Denmark; 20Department
of Urology, Herlev and Gentofte Hospital, Copenhagen University Hospital,
Herlev Ringvej 75, DK-2730 Herlev, Denmark; 21Department of Clinical
Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital,
Herlev Ringvej 75, DK-2730 Herlev, Denmark; 22Faculty of Health and Medical
Sciences, University of Copenhagen, Denmark; 23Cancer Epidemiology Unit,
Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK;
24Department of Epidemiology and Biostatistics, School of Public Health,
Imperial College, London, UK; 25CR-UK/YCR Sheffield Cancer Research Centre,
University of Sheffield, Sheffield, UK; 26University of Cambridge, Department
of Oncology, Box 279, Addenbrooke’s Hospital, Hills Road Cambridge CB2
0QQ, UK; 27School of Social and Community Medicine, University of Bristol,
Canynge Hall, 39 Whatley Road, Bristol, BS8 2PS, UK; 28Nuffield Department
of Surgical Sciences, Faculty of Medical Science, University of Oxford, John
Radcliffe Hospital, Oxford, UK; 29Centre for Cancer Genetic Epidemiology,
Department of Oncology, University of Cambridge, Strangeways Laboratory,
Worts Causeway, Cambridge, UK; 30International Epidemiology Institute, 1555
Research Blvd., Suite 550, Rockville, MD 20850, USA; 31Department of
Epidemiology, Harvard School of Public Health, 677 Huntington Avenue,
Boston, MA 02115, USA; 32Division of Epidemiology, Department of Medicine,
Vanderbilt University Medical Center, 2525 West End Avenue, Suite 800,
Nashville, TN 37232, USA; 33Mayo Clinic, Rochester, MN, USA; 34Department
of Urology, University Hospital Ulm, Germany; 35Department of Urology,
Klinikum rechts der Isar der Technischen Universitaet Muenchen, Munich,
Germany; 36Institute of Human Genetics, University Hospital Ulm, Germany;
37International Hereditary Cancer Center, Department of Genetics and
Pathology, Pomeranian Medical University, Szczecin, Poland; 38Division of
Clinical Epidemiology and Aging Research, German Cancer Research Center
(DKFZ), 69120 Heidelberg, Germany; 39Saarland Cancer Registry, 66119
Saarbruecken, Germany; 40Department of Cancer Epidemiology, Moffitt
Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA, 41Biostatistics
Program, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612,
USA; 42Department of Urology and Alexandrovska University Hospital, Medical
University, Sofia, Bulgaria; 43Department of General and Clinical Pathology,
Medical University, Sofia, Bulgaria; 44Department of Medical Chemistry and
Biochemistry, Molecular Medicine Center, Medical University, Sofia, 2 Zdrave Str.,
1431 Sofia, Bulgaria; 45Australian Prostate Cancer BioResource, Brisbane, Australia;
46Australian Prostate Cancer Research Centre-Queensland, Institute of Health and
Biomedical Innovation and School of Biomedical Science, Queensland University
of Technology, Brisbane, Australia; 47Molecular Cancer Epidemiology Laboratory,
Queensland Institute of Medical Research, Brisbane, Australia; 48Department of
Genetics, Portuguese Oncology Institute, Porto, Portugal; 49The University of Surrey,
Guildford, Surrey, GU2 7XH, UK.
Author details
1School of Social and Community Medicine, University of Bristol, Bristol, UK.
2MRC Integrative Epidemiology Unit at the University of Bristol, Bristol, UK.
3National Institute for Health Research, Bristol Biomedical Research Unit in
Nutrition, Bristol, UK. 4Nuffield Department of Surgery, University of Oxford,
Oxford, UK. 5Surgical Oncology (Uro-Oncology: S4), University of Cambridge,
Box 279, Addenbrooke’s Hospital, Hills Road, Cambridge, UK. 6The Institute of
Cancer Research, 15 Cotswold Road, Sutton SM2 5NG Surrey, UK. 7The Royal
Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK.
8Centre for Cancer Genetic Epidemiology, Department of Public Health and
Primary Care, University of Cambridge, Strangeways Research Laboratory,
Worts Causeway, Cambridge, UK. 9University of Warwick, Coventry, UK.
10Institute of Population Health, The University of Manchester, Manchester
M13 9PL, UK. 11The Cancer Council Victoria, 615 St. Kilda Road, Melbourne,
Victoria 3004, Australia. 12Centre for Epidemiology and Biostatistics,
Melbourne School of Population and Global Health, The University of
Melbourne, Melbourne, Victoria 3010, Australia. 13Department of Medical
Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden.
14Department of Preventive Medicine, Keck School of Medicine, University of
Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA,
USA. 15Department of Medical Biochemistry and Genetics, University of
Turku, Turku, Finland. 16Institute of Biomedical Technology/BioMediTech,
University of Tampere and FimLab Laboratories, Tampere, Finland.
17Department of Clinical Biochemistry, Herlev Hospital, Copenhagen
University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark. 18Cancer
Epidemiology Unit, Nuffield Department of Clinical Medicine, University of
Oxford, Oxford, UK. 19Centre for Cancer Genetic Epidemiology, Department
of Oncology, University of Cambridge, Strangeways Research Laboratory,
Worts Causeway, Cambridge, UK. 20Department of Applied Health Research,
University College London, 1-19 Torrington Place, London WC1E 7HB, UK.
21Cambridge Institute of Public Health, University of Cambridge, Forvie Site,
Robinson Way, Cambridge CB2 0SR, UK. 22Division of Public Health Sciences,
Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 23Department of
Epidemiology, School of Public Health, University of Washington, Seattle, WA,
USA. 24International Epidemiology Institute, 1455 Research Blvd., Suite 550,
Rockville, MD 20850, USA. 25Mayo Clinic, Rochester, MN, USA. 26Department
of Urology, University Hospital Ulm, Ulm, Germany. 27Institute of Human
Genetics, University Hospital Ulm, Ulm, Germany. 28Brigham and Women’s
Hospital/Dana-Farber Cancer Institute, 45 Francis Street - ASB II-3, Boston, MA
02115, USA. 29Washington University, St Louis, MO, USA. 30International
Hereditary Cancer Center, Department of Genetics and Pathology,
Pomeranian Medical University, Szczecin, Poland. 31Division of Genetic
Epidemiology, Department of Medicine, University of Utah School of
Medicine, Salt Lake City, UT, USA. 32Division of Clinical Epidemiology and
Bonilla et al. BMC Medicine  (2016) 14:66 Page 9 of 11
Aging Research, German Cancer Research Center (DKFZ), Heidelberg,
Germany. 33Division of Preventive Oncology, German Cancer Research
Center (DKFZ), Heidelberg, Germany. 34German Cancer Consortium (DKTK),
German Cancer Research Center (DKFZ), Heidelberg, Germany. 35Division of
Cancer Prevention and Control, H. Lee Moffitt Cancer Center, 12902
Magnolia Dr., Tampa, FL, USA. 36Molecular Medicine Center and Department
of Medical Chemistry and Biochemistry, Medical University-Sofia, 2 Zdrave St.,
Sofia 1431, Bulgaria. 37Australian Prostate Cancer Research Centre – Qld,
Institute of Health and Biomedical Innovation and School of Biomedical
Sciences, Queensland University of Technology, Brisbane, Australia.
38Department of Genetics, Portuguese Oncology Institute, Porto, Portugal.
39Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal.
40The University of Surrey, Guildford, Surrey GU2 7XH, UK. 41Commissariat à
l’Energie Atomique, Center National de Génotypage, Evry, France. 42McGill
University-Génome Québec Innovation Centre, Montreal, Canada.
Received: 20 November 2015 Accepted: 16 March 2016
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer
statistics. CA Cancer J Clin. 2011;61:69–90.
2. Sakr WA, Haas GP, Cassin BF, Pontes JE, Crissman JD. The frequency of
carcinoma and intraepithelial neoplasia of the prostate in young male
patients. J Urol. 1993;150:379–85.
3. Sutcliffe S, Colditz GA. Prostate cancer: is it time to expand the research
focus to early-life exposures? Nat Rev Cancer. 2013;13:208–518.
4. Salonia A, Abdollah F, Capitanio U, Suardi N, Gallina A, Castagna G, Clementi MC,
Briganti A, Rigatti P, Montorsi F. Circulating sex steroids and prostate cancer:
introducing the time-dependency theory. World J Urol. 2013;31:267–73.
5. Rowlands M-A, Gunnell D, Harris R, Vatten LJ, Holly JMP, Martin RM.
Circulating insulin-like growth factor peptides and prostate cancer risk: a
systematic review and meta-analysis. Int J Cancer. 2009;124:2416–29.
6. Isbarn H, Pinthus JH, Marks LS, Montorsi F, Morales A, Morgentaler A, Schulman C.
Testosterone and prostate cancer: revisiting old paradigms. Eur Urol. 2009;56:48–56.
7. García-Closas M, Brinton LA, Lissowska J, Chatterjee N, Peplonska B,
Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W,
Blair A, Kalaylioglu Z, Rymkiewicz G, Mazepa-Sikora D, Kordek R, Lukaszek S,
Sherman ME. Established breast cancer risk factors by clinically important
tumour characteristics. Br J Cancer. 2006;95:123–9.
8. Perry JRB, Day F, Elks CE, Sulem P, Thompson DJ, Ferreira T, He C, Chasman DI,
Esko T, Thorleifsson G, Albrecht E, Ang WQ, Corre T, Cousminer DL, Feenstra B,
Franceschini N, Ganna A, Johnson AD, Kjellqvist S, Lunetta KL, McMahon G,
Nolte IM, Paternoster L, Porcu E, Smith A V., Stolk L, Teumer A, Tšernikova N,
Tikkanen E, Ulivi S, et al. Parent-of-origin-specific allelic associations among
106 genomic loci for age at menarche. Nature. 2014;514:92–7.
9. Cousminer DL, Stergiakouli E, Berry DJ, Ang W, Groen-Blokhuis MM, Körner A,
Siitonen N, Ntalla I, Marinelli M, Perry JRB, Kettunen J, Jansen R, Surakka I, Timpson
NJ, Ring S, Mcmahon G, Power C, Wang C, Kähönen M, Viikari J, Lehtimäki T,
Middeldorp CM, Hulshoff Pol HE, Neef M, Weise S, Pahkala K, Niinikoski H, Zeggini
E, Panoutsopoulou K, Bustamante M, et al. Genome-wide association study of
sexual maturation in males and females highlights a role for body mass and
menarche loci in male puberty. Hum Mol Genet. 2014;23:4452–64.
10. Tanner JM, Whitehouse RH. Clinical longitudinal standards for height,
weight, height velocity, weight velocity, and stages of puberty. Arch Dis
Child. 1976;51:170–9.
11. Davey Smith G, Ebrahim S. “Mendelian randomization”: can genetic
epidemiology contribute to understanding environmental determinants of
disease? Int J Epidemiol. 2003;32:1–22.
12. Palmer TM, Lawlor DA, Harbord RM, Sheehan NA, Tobias JH, Timpson NJ,
Davey Smith G, Sterne JAC. Using multiple genetic variants as instrumental
variables for modifiable risk factors. Stat Methods Med Res. 2012;21:223–42.
13. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL. Latest
results from the UK trials evaluating prostate cancer screening and
treatment: the CAP and ProtecT studies. Eur J Cancer. 2010;46:3095–101.
14. Lane JA, Donovan JL, Davis M, Walsh E, Dedman D, Down L, Turner EL,
Mason MD, Metcalfe C, Peters TJ, Neal DE, Hamdy FC. Active monitoring,
radical prostatectomy, or radiotherapy for localised prostate cancer: study
design and diagnostic and baseline results of the ProtecT randomised
phase 3 trial. Lancet Oncol. 2014;15:1109–18.
15. Ohori M, Wheeler TM, Scardino PT. The New American Joint Committee on
Cancer and International Union Against Cancer TNM classification of
prostate cancer. Clinicopathologic correlations. Cancer. 1994;74:104–14.
16. Elks CE, Perry JRB, Sulem P, Chasman DI, Franceschini N, He C, Lunetta KL,
Visser J a, Byrne EM, Cousminer DL, Gudbjartsson DF, Esko T, Feenstra B,
Hottenga J-J, Koller DL, Kutalik Z, Lin P, Mangino M, Marongiu M, McArdle PF,
Smith A V, Stolk L, van Wingerden SH, Zhao JH, Albrecht E, Corre T, Ingelsson E,
Hayward C, Magnusson PKE, Smith EN, et al. Thirty new loci for age at
menarche identified by a meta-analysis of genome-wide association studies.
Nat Genet. 2010;42:1077–85.
17. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
instruments: effect estimation and bias detection through Egger regression.
Int J Epidemiol. 2015;44:512–25.
18. Burgess S, Scott RA, Timpson NJ, Davey Smith G, Thompson SG. Using
published data in Mendelian randomization: a blueprint for efficient
identification of causal risk factors. Eur J Epidemiol. 2015;30:543–52.
19. Lorentzon M, Norjavaara E, Kindblom JM. Pubertal timing predicts leg
length and childhood body mass index predicts sitting height in young
adult men. J Pediatr. 2011;158:452–7.
20. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival
among men with conservatively treated localized prostate cancer. JAMA.
1995;274:626–31.
21. Habel LA, Van Den Eeden SK, Friedman GD. Body size, age at shaving initiation,
and prostate cancer in a large, multiracial cohort. Prostate. 2000;43:136–43.
22. Grossmann M, Cheung AS, Zajac JD. Androgens and prostate cancer;
pathogenesis and deprivation therapy. Best Pract Res Clin Endocrinol
Metab. 2013;27:603–16.
23. Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J,
Körner A, Obermayer-Pietsch B, Hübener C, Dahlgren J, Frystyk J, Pfeiffer AFH,
Doering A, Bielohuby M, Wallaschofski H, Arafat AM. Reference intervals for
insulin-like growth factor-1 (IGF-I) from birth to senescence: results from a
multicenter study using a new automated chemiluminescence IGF-I
immunoassay conforming to recent international recommendations.
J Clin Endocrinol Metab. 2014;99:1712–21.
24. Sandhu J, Davey Smith G, Holly J, Cole TJ, Ben-Shlomo Y. Timing of puberty
determines serum insulin-like growth factor-I in late adulthood. J Clin
Endocrinol Metab. 2006;91:3150–7.
25. McIntyre MH. Adult stature, body proportions and age at menarche in the
United States National Health and Nutrition Survey (NHANES) III. Ann Hum
Biol. 2011;38:716–20.
26. Rogers I, Metcalfe C, Gunnell D, Emmett P, Dunger D, Holly J. Insulin-like
growth factor-I and growth in height, leg length, and trunk length between
ages 5 and 10 years. J Clin Endocrinol Metab. 2006;91:2514–9.
27. Belsky J, Steinberg L, Draper P. Childhood experience, interpersonal
development, and reproductive strategy: and evolutionary theory of
socialization. Child Dev. 1991;62:647–70.
28. Thomas F, Elguero E, Brodeur J, Roche B, Missé D, Raymond M. Malignancies
and high birth weight in human: which cancers could result from antagonistic
pleiotropy? J Evol Med. 2012;1:1–5.
29. Chan Y, Salem RM, Hsu Y-HH, McMahon G, Pers TH, Vedantam S, Esko T,
Guo MH, Lim ET, Franke L, Smith GD, Strachan DP, Hirschhorn JN. Genome-
wide analysis of body proportion classifies height-associated variants by
mechanism of action and implicates genes important for skeletal
development. Am J Hum Genet. 2015;96:695–708.
30. Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for
causal inference in epidemiological studies. Hum Mol Genet. 2014;23:R89–98.
31. Velie EM, Nechuta S, Osuch JR. Lifetime reproductive and anthropometric risk
factors for breast cancer in postmenopausal women. Breast Dis. 2006;24:17–35.
32. Barba M, Terrenato I, Schünemann HJ, Fuhrman B, Sperati F, Teter B,
Gallucci M, D’Amato A, Muti P. Indicators of sexual and somatic
development and adolescent body size in relation to prostate cancer risk:
results from a case-control study. Urology. 2008;72:183–7.
33. Andersson SO, Baron J, Bergström R, Lindgren C, Wolk A, Adami HO.
Lifestyle factors and prostate cancer risk: a case-control study in Sweden.
Cancer Epidemiol Biomarkers Prev. 1996;5:509–13.
34. Honda GD, Bernstein L, Ross RK, Greenland S, Gerkins V, Henderson BE.
Vasectomy, cigarette smoking, and age at first sexual intercourse as risk factors
for prostate cancer in middle-aged men. Br J Cancer. 1988;57:326–31.
35. Schuman LM, Mandel J, Blackard C, Bauer H, Scarlett J, McHugh R.
Epidemiologic study of prostatic cancer: preliminary report. Cancer Treat
Rep. 1977;61:181–6.
Bonilla et al. BMC Medicine  (2016) 14:66 Page 10 of 11
36. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and
prostate cancer. Epidemiology. 2002;13:72–9.
37. Giles GG, Severi G, English DR, McCredie MRE, MacInnis R, Boyle P, Hopper JL.
Early growth, adult body size and prostate cancer risk. Int J Cancer.
2003;103:241–5.
38. Hayes RB, de Jong FH, Raatgever J, Bogdanovicz J, Schroeder FH, van der
Maas P, Oishi K, Yoshida O. Physical characteristics and factors related to
sexual development and behaviour and the risk for prostatic cancer.
Eur J Cancer Prev. 1992;1:239–45.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bonilla et al. BMC Medicine  (2016) 14:66 Page 11 of 11
